Keros Therapeutics, Inc. (KROS) 8-K Current Report: February 26, 2026
Filed: February 26, 2026
Health Care
Pharmaceutical PreparationsKeros Therapeutics, Inc. (KROS) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 5.02: Departure/Election of Directors or Officers
- Item 7.01: Regulation FD Disclosure
Keros Therapeutics, Inc. 8-K Feb 26, 2026 Event Analysis
Item 5.02 · Departure/Election of Directors or Officers
- • Dr. Carl Gordon resigned from Board and Compensation Committee effective March 9, 2026; no disagreement with Company cited
- • Charles Newton appointed Class III director effective March 9, 2026; joins Compensation and Audit Committees — direct replacement for Gordon
- • Initial equity grants: $150,000 stock options + $150,000 RSUs, each capped at 0.075% of shares outstanding, vesting over 3 years quarterly
- • Annual equity grants: $75,000 options + $75,000 RSUs; cash retainer $41,500/year plus $7,000 (Compensation) and $8,500 (Audit) committee fees
- • All equity vests immediately upon Change in Control — relevant given KROS's biotech stage and potential M&A exposure
Item 7.01 · Regulation FD Disclosure
- • Director changes announced via press release dated February 26, 2026 — details in accompanying exhibit
- • Reg FD disclosure ensures all investors receive board change information simultaneously
Other Keros Therapeutics, Inc. 8-K Filings
Get deeper insights on Keros Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.